Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Ruzinurad (SHR4640) in Healthy Subjects
NCT02815839Phase 1Completed
- Sponsor
- Hengrui
- Start
- Nov 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ruzinurad in gout and hyperuricemia (5 cohorts), sponsored by Hengrui. Primary endpoint: Adverse events at Day 19. Started Nov 2015; status: completed.
02
Drugs
ruzinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT02815839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02815839.